A Phase 3 interventional study of Tafamidis and Tafamidis in Transthyretin (TTR) Amyloid Cardiomyopathy, sponsored by Pfizer. Completed at 80 sites in 13 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-04-24.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.
Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 6th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2013, is one of 14 in phase 3, and was the 7th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 30–80
University of Minnesota · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 17 · Phase 4 6
First in 2006; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 441 is above the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 53 across the 38 interventional studies, 125 across the 20 observational. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 58 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyloid Neuropathies, Familial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05619302Phase 3Brigham and Women's HospitalMolecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis | 2026-12-31 |
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT07196839University of Texas Southwestern Medical CenterDetermining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study | 2026-12 |
| NCT07583823University of MinnesotaElevated Rate Pacing of Cardiac Amyloidosis | 2026-12-04 |
| NCT07062848Yale UniversityAn Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems. | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
Phase 3, multicenter, global, three-arm, parallel design, placebo-controlled, double-blind, randomized study to determine efficacy, safety and tolerability of tafamidis on clinical outcomes (all-cause mortality and frequency of cardiovascular-related hospitalizations) in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Treatment-Low dose
Drug: Tafamidis
Active Treatment-High Dose
Drug: Tafamidis
Placebo control
Drug: Placebo
Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations
All-cause mortality and frequency of cardiovascular hospitalization were analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality and frequency of CV-related hospitalizations in a hierarchical fashion using all-cause mortality first. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total "wins" for each treatment group from performing such a hierarchical comparison across all 4 strata in the study.
Time frame: Baseline up to Month 30
All-Cause Mortality
Number of deaths due to any cause was analyzed. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device were handled in the same manner as death.
Time frame: Baseline up to Month 30
Frequency of Cardiovascular-Related Hospitalizations
CV related hospitalizations per year is calculated as participant's number of CV related hospitalizations upon duration on study in years.
Time frame: Baseline to Month 30
Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 30
6MWT is the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.
Time frame: Baseline, Month 30
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). Two summary scores were also calculated: Clinical Summary (calculated as mean of Physical limitation and Total symptom scores) and Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores). Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.
Time frame: Baseline, Month 30
Number of Participants With Cardiovascular-Related Mortality
Deaths adjudicated as CV-related and indeterminate are reported. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death.
Time frame: Baseline up to Month 30
Percentage of Participants With Stabilized Transthyretin (TTR) at Month 1
TTR stabilization is a measure of the degree of stabilization afforded the TTR molecule by tafamidis.
Time frame: Month 1
| Milestone | Tafamidis 20 mg | Tafamidis 80 mg | Placebo |
|---|---|---|---|
| Started | 88 | 176 | 177 |
| Completed | 60 | 113 | 85 |
| Not completed | 28 | 63 | 92 |
| Withdrew: Adverse event | 5 | 12 | 11 |
| Withdrew: Cardiac device implantation | 0 | 2 | 0 |
| Withdrew: Organ transplantation | 1 | 5 | 5 |
| Withdrew: No longer willing to participate | 8 | 17 | 37 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Death | 14 | 25 | 38 |
All-cause mortality and frequency of cardiovascular hospitalization were analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality and frequency of CV-related hospitalizations in a hierarchical fashion using all-cause mortality first. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total "wins" for each treatment group from performing such a hierarchical comparison across all 4 strata in the study.
| wins | Tafamidis | Placebo |
|---|---|---|
| Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations | 8595 | 5071 |
Number of deaths due to any cause was analyzed. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device were handled in the same manner as death.
| Participants | Tafamidis | Placebo |
|---|---|---|
| Deaths (all causes) | 69 | 72 |
| Heart transplants | 7 | 4 |
| Cardiac Mechanical Assist Devices | 2 | 0 |
CV related hospitalizations per year is calculated as participant's number of CV related hospitalizations upon duration on study in years.
| CV hospitalization per year | Tafamidis | Placebo |
|---|---|---|
| Frequency of Cardiovascular-Related Hospitalizations | 0.999 ± 2.2777 | 0.884 ± 1.2032 |
6MWT is the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.
| meters | Tafamidis | Placebo |
|---|---|---|
| Baseline | 350.55 ± 121.296 | 353.26 ± 125.983 |
| Change at Month 30 | -30.46 ± 87.886 | -89.67 ± 105.159 |
KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). Two summary scores were also calculated: Clinical Summary (calculated as mean of Physical limitation and Total symptom scores) and Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores). Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.
| units on a scale | Tafamidis | Placebo |
|---|---|---|
| Baseline | 67.274 ± 21.3561 | 65.898 ± 21.7357 |
| Change at Month 30 | -3.855 ± 19.3075 | -14.637 ± 21.4078 |
Deaths adjudicated as CV-related and indeterminate are reported. Participants who discontinued for transplantation (heart transplantation and combined heart and liver transplantation) or for implantation of a cardiac mechanical assist device, were handled in the same manner as death.
| Participants | Tafamidis | Placebo |
|---|---|---|
| Number of Participants With Cardiovascular-Related Mortality | 64 | 63 |
TTR stabilization is a measure of the degree of stabilization afforded the TTR molecule by tafamidis.
| percentage of participants | Tafamidis | Placebo |
|---|---|---|
| Percentage of Participants With Stabilized Transthyretin (TTR) at Month 1 | 86.1 | 3.5 |
Collected over Baseline up to 28 days after last dose of study drug (Month 31). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis 20 mg | 23/88 (26.1%) | 66/88 (75%) | 86/88 (97.7%) |
| Tafamidis 80 mg | 49/176 (27.8%) | 133/176 (75.6%) | 170/176 (96.6%) |
| Placebo | 72/177 (40.7%) | 140/177 (79.1%) | 171/177 (96.6%) |
| Event | Tafamidis 20 mg | Tafamidis 80 mg | Placebo |
|---|---|---|---|
| Cardiac failureCardiac disorders | 16/88 | 34/176 | 39/177 |
| Cardiac failure congestiveCardiac disorders | 15/88 | 20/176 | 32/177 |
| Cardiac failure acuteCardiac disorders | 4/88 | 23/176 | 17/177 |
| Acute kidney injuryRenal and urinary disorders | 9/88 | 13/176 | 15/177 |
| Atrial fibrillationCardiac disorders | 7/88 | 11/176 | 8/177 |
| PneumoniaInfections and infestations | 6/88 | 13/176 | 12/177 |
| FallInjury, poisoning and procedural complications | 5/88 | 9/176 | 5/177 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 5/88 | 6/176 | 4/177 |
| SyncopeNervous system disorders | 0/88 | 6/176 | 10/177 |
| Ventricular tachycardiaCardiac disorders | 2/88 | 2/176 | 7/177 |
| Event | Tafamidis 20 mg | Tafamidis 80 mg | Placebo |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 21/88 | 27/176 | 51/177 |
| FallInjury, poisoning and procedural complications | 24/88 | 38/176 | 40/177 |
| DiarrhoeaGastrointestinal disorders | 10/88 | 22/176 | 39/177 |
| Cardiac failureCardiac disorders | 18/88 | 20/176 | 33/177 |
| NauseaGastrointestinal disorders | 9/88 | 20/176 | 36/177 |
| Oedema peripheralGeneral disorders | 17/88 | 29/176 | 31/177 |
| FatigueGeneral disorders | 16/88 | 29/176 | 33/177 |
| DizzinessNervous system disorders | 16/88 | 25/176 | 32/177 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/88 | 20/176 | 30/177 |
| Atrial fibrillationCardiac disorders | 13/88 | 28/176 | 31/177 |
The intent-to-treat (ITT) analysis set included all participants in the safety population (all randomized participants who received at least 1 dose of double-blind medication) who had at least 1 post baseline efficacy evaluation ( post baseline hospitalization, study visit, or date of death).
| Age, Continuous(years) | Tafamidis 20 mg | Tafamidis 80 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 73.3 ± 7.07 | 75.2 ± 7.24 | 74.1 ± 6.69 | 74.3 ± 7.01 |
| Sex: Female, Male(Participants) | Tafamidis 20 mg | Tafamidis 80 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 5 | 18 | 20 | 43 |
| Male | 83 | 158 | 157 | 398 |
| Ethnicity (NIH/OMB)(Participants) | Tafamidis 20 mg | Tafamidis 80 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 | 14 |
| Not Hispanic or Latino | 84 | 171 | 170 | 425 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Tafamidis 20 mg | Tafamidis 80 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 11 | 5 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 11 | 26 | 26 | 63 |
| White | 75 | 136 | 146 | 357 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2013 to primary completion in Feb 2018, 49 months.
Results were first posted in Apr 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis
Amyloid Neuropathies, Familial →